APA (7th ed.) Citation

Yeter Hasan H., Derici Ulver, Arinsoy Turgay, Altok Kadriye, Erten Yasemin, & Guz Galip. (2022). Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome. Sciendo.

Chicago Style (17th ed.) Citation

Yeter Hasan H., Derici Ulver, Arinsoy Turgay, Altok Kadriye, Erten Yasemin, and Guz Galip. Discontinuation of Eculizumab Treatment After Hematological Remission in Patients with Atypical and Drug-induced Hemolytic Uremic Syndrome. Sciendo, 2022.

MLA (9th ed.) Citation

Yeter Hasan H., et al. Discontinuation of Eculizumab Treatment After Hematological Remission in Patients with Atypical and Drug-induced Hemolytic Uremic Syndrome. Sciendo, 2022.